News

While the injections from Lilly and Novo have revolutionized the way obesity is treated, investors say pills are key to ...
Eli Lilly (LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Investing.com - Shares in Eli Lilly (NYSE: LLY) sank by over 12% in premarket U.S. trading on Thursday after a study showed that the pharmaceutical giant’s weight-loss pill cut body weight by less ...
Earnings, adjusted for one-time gains and costs, came to $6.31 per share. The results surpassed Wall Street expectations. The ...
In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...
However, shares of the U.S. drugmaker fell about 12% in premarket trading after it reported data from its oral weight loss ...
Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...
Shares of Eli Lilly and Co. (LLY) tumbled 12.8% in premarket trading Thursday, toward its biggest one-day selloff in 26 years, after the drug giant disclosed late-stage trial data for its oral ...
Eli Lilly (LLY) stock dips as the company reports Phase 3 trial results for its oral obesity drug orforglipron. Read more ...
Trump’s tariffs, including new levies that took effect Thursday, are affecting global markets. Follow along for live updates on the Dow, S&P 500 and Nasdaq.
As households combining three-plus generations become more common, advisors have an opportunity to address their needs.